Severe hypoglycaemia after long-acting octreotide in a patient with an unrecognized malignant insulinoma

Internal Medicine Journal

Volumn 37, Issue 6, 2007, Pages 406-409

  Healy, M L ^a   Dawson, S J ^a   Murray, R M L ^a   Zalcberg, J ^a,b   Jefford, M ^a,b,c  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c PETER MACCALLUM CANCER CENTRE   (Australia)

Author keywords

Hypoglycaemia; Insulinoma; Octreotide

Indexed keywords

ALPHA FETOPROTEIN; C PEPTIDE; CARCINOEMBRYONIC ANTIGEN; CHORIONIC GONADOTROPIN BETA SUBUNIT; CHROMOGRANIN A; GLUCOSE; INSULIN; OCTREOTIDE; PEROXIDASE; PROINSULIN; SOMATOSTATIN RECEPTOR; TUMOR MARKER;

ABDOMINAL PAIN; ADULT; ANOREXIA; ARTICLE; ASCITES; BRAIN INJURY; CACHEXIA; CANCER CENTER; CARCINOID; CASE REPORT; COLONOSCOPY; COMPUTER ASSISTED TOMOGRAPHY; DRUG UPTAKE; FATIGUE; GASTROSCOPY; GLASGOW COMA SCALE; GLUCOSE BLOOD LEVEL; HEPATOMEGALY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYPOGLYCEMIA; IMMUNOPEROXIDASE STAINING; INSULIN BLOOD LEVEL; INSULINOMA; LIVER BIOPSY; LIVER DISEASE; LIVER FUNCTION TEST; LIVER METASTASIS; LYMPHADENOPATHY; MALE; MORPHOLOGY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; ULTRASOUND; WEIGHT REDUCTION;

ADULT; DELAYED-ACTION PREPARATIONS; HUMANS; HYPOGLYCEMIA; INSULINOMA; MALE; OCTREOTIDE; PANCREATIC NEOPLASMS;

EID: 34447094133     PISSN: 14440903     EISSN: 14455994     Source Type: Journal    
DOI: 10.1111/j.1445-5994.2007.01371.x     Document Type: Article

References (17)

1. Service FJ, McMahon MM, O'Brien PC, Ballard DJ. Functioning insulinoma - incidence, recurrence, and long-term survival of patients: a 60-year study. Mayo Clin Proc 1991 66 : 711 9.
2. Gama R, Marks V, Wright J, Teale JD. Octreotide exacerbated fasting hypoglycaemia in a patient with a proinsulinoma; the glucostatic importance of pancreatic glucagon. Clin Endocrinol 1995 43 : 117 20 discussion 120-2.
3. Stehouwer CD, Lems WF, Fischer HR, Hackeng WH, Naafs MA. Aggravation of hypoglycemia in insulinoma patients by the long-acting somatostatin analogue octreotide (Sandostatin). Acta Endocrinol 1989 121 : 34 40.
4. Warner RR. Enteroendocrine tumors other than carcinoid: a review of clinically significant advances. Gastroenterology 2005 128 : 1668 84.
5. Hirshberg B, Cochran C, Skarulis MC, Libutti SK, Alexander HR, Wood BJ et al. Malignant insulinoma: spectrum of unusual clinical features. Cancer 2005 104 : 264 72.
6. O'Connor DT, Deftos LJ. Secretion of chromogranin A by peptide-producing endocrine neoplasms. N Engl J Med 1986 314 : 1145 51.
7. Hirshberg B, Livi A, Bartlett DL, Libutti SK, Alexander HR, Doppman JL et al. Forty-eight-hour fast: the diagnostic test for insulinoma. J Clin Endocrinol Metab 2000 85 : 3222 6.
8. World Health Organization. WHO Classification of Tumors. In : Lloyd R, Heitz P, Eng C, eds. Pathology and Genetics of Tumors of Endocrine Organs Geneva : WHO Press 2004.
9. Viola KV, Sosa JA. Current advances in the diagnosis and treatment of pancreatic endocrine tumors. Curr Opin Oncol 2005 17 : 24 7.
10. Oberg K, Kvols L, Caplin M, Delle Fave G, de Herder W, Rindi G et al. Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system. Ann Oncol 2004 15 : 966 73.
11. Lamberts SW, van der Lely AJ, de Herder WW, Hofland LJ. Octreotide. N Engl J Med 1996 334 : 246 54.
12. Lamberts SW, Krenning EP, Reubi JC. The role of somatostatin and its analogs in the diagnosis and treatment of tumors. Endocr Rev 1991 12 : 450 82.
13. Longnecker SM. Remission of symptoms of chemotherapy-refractory metastatic insulinoma using octreotide. Drug Intell Clin Pharm 1988 22 : 136 8.
14. Shojamanesh H, Gibril F, Louie A, Ojeaburu JV, Bashir S, Abou-Saif A et al. Prospective study of the antitumor efficacy of long-term octreotide treatment in patients with progressive metastatic gastrinoma. Cancer 2002 94 : 331 43.
15. Stewart PM, Kane KF, Stewart SE, Lancranjan I, Sheppard MC. Depot long-acting somatostatin analog (Sandostatin-LAR) is an effective treatment for acromegaly. J Clin Endocrinol Metab 1995 80 : 3267 72.
16. Immerman SC, Sener SF, Khandekar JD. Causes and evaluation of tumor-induced hypoglycemia. Arch Surg 1982 117 : 905 8.
17. Kubota A, Yamada Y, Kagimoto S, Shimatsu A, Imamura M, Tsuda K et al. Identification of somatostatin receptor subtypes and an implication for the efficacy of somatostatin analogue SMS 201-995 in treatment of human endocrine tumors. J Clin Invest 1994 93 : 1321 5.